-
Product Insights
NewLikelihood of Approval Analysis for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Overview How likely is it that the drugs in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)...
-
Product Insights
NewLikelihood of Approval Analysis for Interstitial Lung Fibrosis
Overview How likely is it that the drugs in Interstitial Lung Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interstitial Lung Fibrosis Overview Interstitial Lung Fibrosis or interstitial lung disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Systemic Sclerosis (Scleroderma) Drug Details: efzofitimod (ATYR-1923) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Fibrosis Drug Details: Treprostinil (Tyvaso, Tyvaso DPI) is a...
-
Product Insights
NewLikelihood of Approval Analysis for Idiopathic Pulmonary Fibrosis
Overview How likely is it that the drugs in Idiopathic Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tulisokibart in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tulisokibart in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tulisokibart in Ulcerative Colitis Drug Details: Tulisokibart is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Hypertension Drug Details: Treprostinil (Yutrepia) is a prostacyclin analog...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tulisokibart in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tulisokibart in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tulisokibart in Crohn's Disease (Regional Enteritis) Drug Details: Tulisokibart is...